# Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

> **NCT03274076** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Michigan** · enrollment: 15 (actual)

## Conditions studied

- Systemic Sclerosis
- Scleroderma

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03274076
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-25
- **Primary completion:** 2019-04-08
- **Final completion:** 2019-11-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274076, "Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03274076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*